Understanding Cervical Adenocarcinoma, including Endocervical Adenocarcinoma and Cervical Glandular Cancer, is crucial for accurate clinical documentation and medical coding. This resource provides information on diagnosis, treatment, and ICD-10 codes related to Cervical Adenocarcinoma, supporting healthcare professionals in proper documentation and coding practices. Learn about the latest clinical guidelines and best practices for managing Cervical Glandular Cancer and Endocervical Adenocarcinoma to ensure optimal patient care.
Also known as
Malignant neoplasm of cervix uteri
Cancerous growths affecting the cervix.
Malignant neoplasm of corpus uteri
Cancers originating in the body of the uterus.
Secondary malignant neoplasm of other specified sites
Cancer that has spread to the cervix from elsewhere.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the adenocarcinoma in situ?
Yes
Code C53.9 Cervical carcinoma, unspecified
No
Is it endocervical or exocervical?
When to use each related code
| Description |
|---|
| Cancer in the mucus-producing glands of the cervix. |
| Precancerous changes in cervical glandular cells. |
| Squamous cell cancer of the cervix. |
Insufficient documentation to distinguish between adenocarcinoma in situ (AIS) and invasive adenocarcinoma impacting accurate coding and staging.
Missing laterality (right, left, bilateral, unspecified) for cervical cancer may affect treatment planning and data analysis for quality reporting.
Lack of documented HPV status or incorrect HPV code assignment can impact clinical decision-making and reimbursement linked to specific treatment pathways.
Q: What are the key differentiating features in the diagnostic workup of endocervical adenocarcinoma versus squamous cell carcinoma of the cervix?
A: While both endocervical adenocarcinoma and squamous cell carcinoma affect the cervix, their diagnostic workup presents key differences. Squamous cell carcinoma is often initially suspected based on abnormal Pap smear cytology and confirmed with colposcopy and biopsy. Endocervical adenocarcinoma, however, may present with less obvious cytological changes, sometimes requiring endocervical curettage or cone biopsy for definitive diagnosis. Imaging modalities, such as MRI and PET/CT, play a more significant role in staging endocervical adenocarcinoma to assess the extent of local invasion and lymph node involvement. Immunohistochemistry can also differentiate adenocarcinoma subtypes. Consider implementing a more thorough evaluation for adenocarcinoma when clinical suspicion is high despite negative or equivocal initial cytology. Explore how advanced imaging can contribute to early and accurate diagnosis of cervical adenocarcinoma.
Q: How does the management of stage IB1 cervical adenocarcinoma differ based on histological subtype and patient's desire for future fertility?
A: Management of stage IB1 cervical adenocarcinoma is individualized based on factors such as histological subtype (e.g., mucinous, clear cell, serous) and the patient's desire for future fertility. For patients desiring fertility preservation, radical trachelectomy may be an option in select cases with tumors smaller than 2 cm and favorable histological features. However, this approach requires careful patient selection and thorough counseling regarding potential risks and oncological outcomes. For patients not desiring future fertility, radical hysterectomy with pelvic lymphadenectomy remains the standard of care. The specific extent of lymphadenectomy can be guided by surgical findings and the risk of nodal metastasis based on tumor characteristics. Learn more about the role of sentinel lymph node biopsy in staging and guiding treatment decisions for early-stage cervical cancer.
Patient presents with concerns regarding abnormal vaginal bleeding, post-coital bleeding, and persistent watery discharge. She reports no significant pain. Physical examination reveals a friable lesion on the cervix. Pelvic examination findings suggest possible cervical adenocarcinoma. Differential diagnoses include endocervical adenocarcinoma, cervical glandular cancer, cervical squamous cell carcinoma, and cervical polyps. Given the clinical presentation and examination findings, cervical adenocarcinoma is the leading differential diagnosis. A biopsy was performed and sent for histopathological examination. Preliminary findings suggest adenocarcinoma of the cervix. Patient was counseled on the potential diagnosis of cervical adenocarcinoma, treatment options including surgery, radiation therapy, and chemotherapy, and the importance of follow-up care. Further diagnostic workup, including imaging studies such as a pelvic MRI and PET scan, will be performed to assess the extent of the disease and determine appropriate staging. The patient will be referred to a gynecologic oncologist for further management and treatment planning for cervical cancer. ICD-10 code C53.9, malignant neoplasm of cervix uteri, unspecified, is provisionally assigned pending definitive pathology results. This diagnosis may be further specified based on the final pathology report and staging. The patient understands the seriousness of the potential diagnosis and agrees to follow up for further evaluation and treatment.